Clinical Trials Browser

INDUSTRY × Everolimus × CNS × Clear all

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01365468 2016-05-12

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Phase 2 Terminated

9 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00789828 2016-02-03

EXIST-1

Phase 3 Completed

117 enrolled 15 charts

Astrocytoma, Tuberous Sclerosis

NCT00107237 2013-06-12

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Phase 1/2 Completed

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma